onc Videos

Videos

Videos

Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer

07/18/2023

Featuring Tsz Lun Yeung, MD

At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.

At the 2023 ASCO Annual Meeting,...

07/18/2023

Oncology

Paul Paik, MD, Memorial Sloan Kettering Cancer Center

Videos

Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer

07/17/2023

Featuring Paul Paik, MD

At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Ticiana Leal, MD, Winship Cancer Institute

Videos

Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer

07/17/2023

Featuring Ticiana Leal, MD

At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Videos

Targeting KRAS in Gastrointestinal Cancers

07/14/2023

At the 2023 World Congress on Gastrointestinal Cancers, John Strickler, MD, reviews the currently available and upcoming strategies in targeting KRAS in gastrointestinal cancers.

At the 2023 World Congress on...

07/14/2023

Oncology

Van Morris, MD, MD Anderson Cancer Center

Videos

Ipilimumab Added to Nivolumab Does Not Significantly Improve Survival Outcomes for Patients With Squamous Cell Carcinoma of the Anal Canal

07/13/2023

Featuring Van Morris, MD

At the 2023 World Congress on Gastrointestinal Cancers, Van Morris, MD, presented results from a phase 2 study evaluating the addition of ipilimumab to nivolumab for patients with previously treated, unresectable or metastatic squamous cell...

At the 2023 World Congress on...

07/13/2023

Oncology

Rachel Purcell, PhD, University of Otago, Christchurch

Videos

Effect of Microbiome on Colorectal Cancer Tumor Microenvironment

07/13/2023

Featuring Rachel Purcell, PhD

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, different microbes in the colorectal cancer tumor microenvironment were found to increase immune activity and potentially have an immunosuppressive effect.

According to a study presented...

07/13/2023

Oncology

Michael White, MD, MD Anderson Cancer Center

Videos

Mutational Signature Similarities and Differences Between Appendiceal Adenocarcinoma and Colorectal Cancer

07/13/2023

Featuring Michael White, MD

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, there were distinct mutational differences noted between appendiceal adenocarcinoma and colorectal cancer.

According to a study presented...

07/13/2023

Oncology

Videos

Treating a Patient With Lower-Risk Myelodysplastic Syndrome

07/12/2023

Featuring Amer Zeidan, MBBS

Amer Zeidan, MBBS, highlights his treatment choices for the case of a 74-year-old patient diagnosed with lower-risk myelodysplastic syndrome (MDS).

Amer Zeidan, MBBS, highlights...

07/12/2023

Oncology

Lucjan Wyrwicz, MD, Maria Sklodowska Curie National Cancer Research Institute

Videos

Continued Benefit From Pembrolizumab Plus Chemotherapy in Later-Line Therapy for Patients With Advanced, HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma

07/12/2023

Featuring Lucjan Wyrwicz, MD

At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...

At the 2023 World Congress on...

07/12/2023

Oncology

James Harding, MD, Memorial Sloan Kettering Cancer Center

Videos

Novel Dual IDH-Inhibitor Plus Chemotherapy Showed Promising Efficacy, Safety for Patients With Advanced IDH-Mutant Cholangiocarcinoma

07/12/2023

Featuring James Harding, MD

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, the IDH1/2-inhibitor LY3410738 showed promising efficacy and safety in combination with chemotherapy for patients with locally advanced or metastatic...

According to a study presented...

07/12/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology